Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

9 evidence topics · 10 sources

Summary
  • Guideline sequencing: the VA/DoD 2025 algorithm prescribes PAP as first-line therapy for severe OSA (AHI above 30 events per hour) and PAP or a mandibular advancement device for an AHI of 5 to below 30, and refers patients who do not adopt or use PAP or a mandibular advancement device to a sleep medicine specialist. The ACP recommends CPAP as initial therapy (strong recommendation, moderate-quality evidence) and mandibular advancement devices as an alternative (weak recommendation, low-quality evidence). The AASM and AADSM recommend that sleep physicians consider oral appliances for adults intolerant of CPAP therapy or preferring alternate therapy. After PAP is unsuccessful or not accepted, guidelines suggest referral for hypoglossal nerve stimulation evaluation when the AHI is 15 or more per hour (VA/DoD) and recommend discussing referral to a sleep surgeon when the BMI is below 40 kg/m2 or to a bariatric surgeon when the BMI is 35 kg/m2 or more (AASM). Wake-promoting agents are suggested for residual excessive daytime sleepiness in patients optimally treated with sufficient therapy use (VA/DoD).
  • VA/DoD 2025 Recommendation 24 suggests against atomoxetine or a combination of atomoxetine and oxybutynin for OSA (“Weak against”). It rests on 2 randomized trials with mixed results, low confidence in the evidence, and known harms (atomoxetine may increase blood pressure; oxybutynin's anticholinergic effects can increase the risk of falls and cause cognitive impairment). The guideline notes that aroxybutynin is not approved by the FDA. Its evidence review ended on March 31, 2024, and it states that randomized trials of these agents as salvage or adjunctive therapy are needed; Apnimed states that both AD109 phase 3 trials, SynAIRgy and LunAIRo, were completed in 2025.
  • AD109 phase 3 population: SynAIRgy and LunAIRo enrolled adults with mild to severe OSA who were intolerant of or refused PAP. PAP failure was defined as no PAP use for at least 3 months before randomization or return or removal of the device, and PAP refusal as refusal of PAP after a positive sleep study or refusal of a recommended sleep study due to unwillingness to consider PAP. In the SynAIRgy intent-to-treat set of 615 participants, 411 (66.8%) had PAP intolerance and 205 (33.3%) PAP refusal.
  • Apnimed's stated positioning: the initial launch would focus on the approximately 10.5 million people in the United States diagnosed with OSA but untreated (from a 2025 National Sleep Foundation survey), then on patients using another treatment whose OSA is not fully resolved (as a complement to PAP or GLP-1 therapies), with first-line use as the long-term target. The company presentation describes the target patient as intolerant to PAP (refused or failed), diagnosed within the past 2 years, and without insomnia or active cardiovascular disease. Apnimed plans 125 to 150 field representatives covering 15,000 to 20,000 sleep specialists and high-volume primary care practices. Company-cited surveys report that 84% of surveyed healthcare providers familiar with Oxnimbi intend to prescribe it (Wells Fargo, August 2025) and that approximately 80% of 1,500 surveyed patients reported likelihood of asking their healthcare provider to try a nightly pill proven to improve OSA (SHINE Survey).
  • An editorial on SynAIRgy describes AD109 as a likely addition to a multimodal treatment framework, particularly for patients unable or unwilling to use PAP.
VA/DoD 2025 Recommendation 24 against atomoxetine or atomoxetine plus oxybutynin

“For treatment of obstructive sleep apnea, we suggest against atomoxetine or a combination of atomoxetine and oxybutynin. (Weak against | Reviewed, New-added)” (opens the source at this quote in a new tab)

“Evidence from 2 RCTs (203,204) provided mixed results on whether atomoxetine or the combination of atomoxetine and oxybutynin improve critical outcomes of obstructive sleep apnea (OSA) such as reductions in apnea hypopnea index (AHI), improvements in daytime functioning, or sleep-related quality of life (QoL).” (opens the source at this quote in a new tab)

“The combination of atomoxetine and aroxybutynin showed a reduction in AHI, daytime fatigue, and respiratory arousal. Aroxybutynin, the R-enantiomer of oxybutynin, is not approved by the FDA and not commercially available.” (opens the source at this quote in a new tab)

“Confidence in the quality of overall evidence was rated as low due to small sample sizes and the risk for imprecision. A weak against recommendation for atomoxetine and the combination of atomoxetine and oxybutynin was made because of known harms from these medications, inconclusive evidence that they are effective in OSA, and the low quality of evidence.” (opens the source at this quote in a new tab)

“Specifically, atomoxetine may increase blood pressure and exacerbate cardiovascular disorders and oxybutynin’s anticholinergic effects can increase risk for falls and cause cognitive impairment.” (opens the source at this quote in a new tab)